South Africa has become the first African country to register lenacapavir, a groundbreaking six-monthly HIV prevention ...

South Africa's Health Product Regulatory Authority (SAHPRA) has approved the use of the twice-yearly HIV prevention drug, lenacapavir. In a statement released on 27 October, the regulatory body said ...

Lenacapavir is a revolutionary long-acting injectable drug that offers six months of protection with just two annual ...

The drug, Lenacapavir, is the world's first injectable Pre-Exposure Prophylaxis (PrEP). According to the World Health ...

South Africa has become the first African country to register the revolutionary twice-a-year anti-HIV jab, lenacapavir (LEN).

An HIV prevention jab that provides six months of protection at a time was given the green light by South Africa's medicines regulator. The approval helps to clear the way for a limited public sector ...

Camber Pharmaceuticals’ parent company, Hetero, a global company specializing in active pharmaceutical ingredients and ...

Gilead Sciences approaches Q3 2025 results on October 30, hitting new highs and presenting Livdelzi data at The Liver Meeting ...

Through a US$ 29 million grant, South Africa will receive enough medicine to provide HIV prevention to 450 000 people at high ...

At the World Health Summit last week in Berlin, Germany announced an additional €2.5 million in core funding to UNAIDS, bringing its total core contribution for 2025 to €5.5 million. Germany also ...

A recently approved twice-yearly injection to prevent HIV may warrant a higher price, but thousands of dollars more?  CVS Caremark’s chief medical officer calls on Gilead Sciences to lower the $28,000 ...

Lenacapavir, a groundbreaking HIV treatment, is set to transform South Africa’s approach to HIV prevention amidst funding ...